Comparing Methods for Assessing Treatment in Brain Metastases: Integrating Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) and Response Evaluation Criteria in Solid Tumors (RECIST) to Improve Response Evaluation
Brain metastasis is cancer that grows in the brain especially when cancer starts spreading, and is a type of cancer that is very difficult to treat.
This project will evaluate how well the treatments for brain metastases work. In order to assess how well the treatments work, there are two methods that are frequently used, called RANO-BM (Response Assessment in Neuro-Oncology Brain Metastasis) and RECIST (Response Evaluation Criteria in Solid Tumours). These methods are tools that doctors use to assess how much a tumor (abnormal growth of cells that forms a lump or mass) has shrunk or responded to treatment.
We will be comparing these two methods using data from several clinical trials together.
This research is necessary because we need to know which of the two methods (RANO-BM or RECIST) is better for patient care.
This analysis requires the pooling of several studies in order to have more patients included in this research, as this will be necessary to answer our research question, ie which of the two methods is better.
Aims and objectives:
- To assess the correlation and level of agreement between Response Evaluation Criteria in Solid Tumors (RECIST) and Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) response categories.
- To evaluate differences between progression-free survival (PFS) by RANO BM and PF by RECIST.
- To compare the strength of the association between PFS by RANO BM and overall survival (OS) to that between PFS by RECIST and OS
Our hypothesis is that RANO-BM will be better than RECIST for patients with brain metastasis.
Project leaders:
- Pablo Leone, DFCI, US
- Manmeet Ahluwalia, CCF, US
- Martin van den Bent, Erasmus, NL